Budd-Chiari syndrome
ICD-10 I82.0 · ICD-11 DB98.5

Treatment of Budd-Chiari Syndrome with Long-Segment Hepatic Vein Thrombosis When Anticoagulation Fails to Resolve Liver Failure, Ascites, or Varices

This protocol addresses patients with Budd-Chiari syndrome caused by long-segment thrombotic occlusion of the hepatic veins who have symptoms of liver failure, ascites, or varices — and in whom initial anticoagulation-based management has not achieved the required clinical milestones at the two-week evaluation.

Clinical Scenario

Long-segment thrombotic occlusion of the hepatic veins represents a more severe form of Budd-Chiari syndrome, associated with significant hepatic and splanchnic congestion. When liver failure, ascites, or varices are present, a portocaval shunting procedure may be required to relieve congestion — and early intervention may be indicated without waiting for a response to medical treatment.

When the Previous Treatment Did Not Work

First-line management consists of anticoagulation with low-molecular-weight heparin (initiated as soon as the diagnosis is made), together with supportive medication as required. Escalation to this protocol is indicated when the two-week evaluation shows that the following targets were not reached: resolution of ascites, a negative sodium and water balance, factor 5 at least 50% of its normal value, and a decrease in conjugated bilirubin if it was initially elevated.

Next-Step Intervention (Partial Overview)

When anticoagulation alone is insufficient, early transjugular intrahepatic portosystemic shunt (TIPS) placement using a PTFE-covered stent is the intervention considered. Precise technical requirements govern the shunt diameter. In patients with additional venous thrombosis, a catheter-based adjunctive approach alongside anticoagulation is defined, with a structured monitoring schedule. The complete parameters and step-by-step algorithm are detailed in the full protocol.

Clinical Goals

The target outcomes include reduction of the portosystemic pressure gradient to approximately 10.8 mmHg and improvement of creatinine concentration to approximately 0.8 mg/dL within two weeks of the intervention.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/diagnostics13081458

View source ↗